Differences in clinical features and comorbid burden between HLA-C∗06:02 carrier groups in >9,000 people with psoriasis.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Douroudis, KonstantinosRamessur, Ravi
Barbosa, Ines A
Baudry, David
Duckworth, Michael
Angit, Caroline
Capon, Francesca
Chung, Raymond
Curtis, Charles J
Di Meglio, Paola
Goulding, Jonathan M R
Griffiths, Christopher E M
Lee, Sang Hyuck
Mahil, Satveer K
Parslew, Richard
Reynolds, Nick J
Shipman, Alexa R
Warren, Richard B
Yiu, Zenas Z N
Simpson, Michael A
Barker, Jonathan N
Dand, Nick
Smith, Catherine H
Publication date
2021-11-10Subject
Genetics
Metadata
Show full item recordAbstract
The identification of robust endotypes-disease subgroups of clinical relevance-is fundamental to stratified medicine. We hypothesized that HLA-C∗06:02 status, the major genetic determinant of psoriasis, defines a psoriasis endotype of clinical relevance. Using two United Kingdom-based cross-sectional datasets-an observational severe-psoriasis study (Biomarkers of Systemic Treatment Outcomes in Psoriasis; n = 3,767) and a large population-based bioresource (UK Biobank, including n = 5,519 individuals with psoriasis)-we compared demographic, environmental, and clinical variables of interest in HLA-C∗06:02-positive (one or two copies of the HLA-C∗06:02 allele) with those in HLA-C∗06:02‒negative (no copies) individuals of European ancestry. We used multivariable regression analyses to account for mediation effects established a priori. We confirm previous observations that HLA-C∗06:02-positive status is associated with earlier age of psoriasis onset and extend findings to reveal an association with disease expressivity in females (Biomarkers of Systemic Treatment Outcomes in Psoriasis: P = 2.7 × 10-14, UK Biobank: P = 1.0 × 10-8). We also show HLA-C∗06:02-negative status to be associated with characteristic clinical features (large plaque disease, OR for HLA-C∗06:02 = 0.73, P = 7.4 × 10-4; nail involvement, OR = 0.70, P = 2.4 × 10-6); higher central adiposity (Biomarkers of Systemic Treatment Outcomes in Psoriasis: waist circumference difference of 2.0 cm, P = 8.4 × 10-4; UK Biobank: waist circumference difference of 1.4 cm, P = 1.5 × 10-4), especially in women; and a higher prevalence of other cardiometabolic comorbidities. These findings extend the clinical phenotype delineated by HLA-C∗06:02 and highlight its potential as an important biomarker to consider in future multimarker stratified medicine approaches.Citation
Douroudis K, Ramessur R, Barbosa IA, Baudry D, Duckworth M, Angit C, Capon F, Chung R, Curtis CJ, Di Meglio P, Goulding JMR, Griffiths CEM, Lee SH, Mahil SK, Parslew R, Reynolds NJ, Shipman AR, Warren RB, Yiu ZZN, Simpson MA, Barker JN, Dand N, Smith CH; BADBIR; BSTOP Study Groups. Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000 People with Psoriasis. J Invest Dermatol. 2022 Jun;142(6):1617-1628.e10. doi: 10.1016/j.jid.2021.08.446. Epub 2021Type
ArticlePMID
34767815Publisher
Elsevierae974a485f413a2113503eed53cd6c53
10.1016/j.jid.2021.08.446